Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
University probe leads to retraction of four neural tube studies
The University of Maryland conducted an internal investigation that identified image duplications and other data integrity issues in the studies, according to the retraction notices.
University probe leads to retraction of four neural tube studies
The University of Maryland conducted an internal investigation that identified image duplications and other data integrity issues in the studies, according to the retraction notices.
Highly cited autism paper earns expression of concern over data duplications
The notice, published in Nature last week, also addressed an image duplication identified by a prominent research-integrity sleuth.
Highly cited autism paper earns expression of concern over data duplications
The notice, published in Nature last week, also addressed an image duplication identified by a prominent research-integrity sleuth.
Govern neurodata by how it’s used, not where it’s from
New neurodata laws will shape how researchers gather, share and reuse brain data. A use-based governance protects basic researchers and those whose data are being used, without freezing science.
Govern neurodata by how it’s used, not where it’s from
New neurodata laws will shape how researchers gather, share and reuse brain data. A use-based governance protects basic researchers and those whose data are being used, without freezing science.